These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 39004098

  • 1. Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis.
    Jenei K, Gentilini A, Haslam A, Prasad V.
    Lancet Oncol; 2024 Aug; 25(8):979-988. PubMed ID: 39004098
    [Abstract] [Full Text] [Related]

  • 2. Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs.
    Pinto A, Naci H, Neez E, Mossialos E.
    Value Health; 2020 Mar; 23(3):319-327. PubMed ID: 32197727
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparative Expedited Regulatory Programs of U.S Food & Drug Administration and Project Orbis Partners.
    Hotaki LT, Shrestha A, Bennett MP, Valdes IL, Lee SH, Wang Y, Spillman D, MacAulay T, Hunt M, Gervais J, Mafi M, Panetta V, Looi YH, Shum M, Atiek E, Meincke R, Rohr UP, Ainbinder D, Boehm-Cagan A, Luxenburg O, Cerqueira MR, Mouawad LS, Thees MFRES, Prasad K, de Claro RA.
    Ther Innov Regul Sci; 2023 Jul; 57(4):875-885. PubMed ID: 37072651
    [Abstract] [Full Text] [Related]

  • 6. Assessment of FDA-Approved Drugs Not Recommended for Use or Reimbursement in Other Countries, 2017-2020.
    Pham C, Le K, Draves M, Seoane-Vazquez E.
    JAMA Intern Med; 2023 Apr 01; 183(4):290-297. PubMed ID: 36780147
    [Abstract] [Full Text] [Related]

  • 7. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
    Cherla A, Naci H, Kesselheim AS, Gyawali B, Mossialos E.
    JAMA Intern Med; 2021 Apr 01; 181(4):490-498. PubMed ID: 33616607
    [Abstract] [Full Text] [Related]

  • 8. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J, Cairns C, Paquette C, Faden L.
    Appl Health Econ Health Policy; 2006 Apr 01; 5(3):177-87. PubMed ID: 17132032
    [Abstract] [Full Text] [Related]

  • 9. Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland.
    Michaeli DT, Mills M, Kanavos P.
    Appl Health Econ Health Policy; 2022 Sep 01; 20(5):757-768. PubMed ID: 35821360
    [Abstract] [Full Text] [Related]

  • 10. Is Canada Moving towards a More Agile Regulatory Approval and Reimbursement Process with a Shifting Role for Real-World Evidence (RWE) for Oncology Drugs?
    Lau CY, Rawson NSB.
    Curr Oncol; 2024 Sep 18; 31(9):5599-5607. PubMed ID: 39330042
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N, Walker SR, Liberti L, Salek S.
    Value Health; 2017 Mar 18; 20(3):320-328. PubMed ID: 28292476
    [Abstract] [Full Text] [Related]

  • 15. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M, Naci H, Davis C.
    Milbank Q; 2020 Dec 18; 98(4):1219-1256. PubMed ID: 33021339
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015.
    Vivot A, Jacot J, Zeitoun JD, Ravaud P, Crequit P, Porcher R.
    Ann Oncol; 2017 May 01; 28(5):1111-1116. PubMed ID: 28453694
    [Abstract] [Full Text] [Related]

  • 18. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S, Browman GP, Hoch JS, Kovacic L, Peacock SJ.
    Oncologist; 2015 Jul 01; 20(7):729-36. PubMed ID: 26032135
    [Abstract] [Full Text] [Related]

  • 19. Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA.
    Michaeli DT, Mills M, Michaeli T, Miracolo A, Kanavos P.
    Invest New Drugs; 2022 Aug 01; 40(4):798-809. PubMed ID: 35389145
    [Abstract] [Full Text] [Related]

  • 20. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
    Lythgoe MP, Desai A, Gyawali B, Savage P, Krell J, Warner JL, Khaki AR.
    JAMA Netw Open; 2022 Jun 01; 5(6):e2216183. PubMed ID: 35687337
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.